Ningalin B analogs employable for reversing multidrug resistance

• US 7,250,409 B2
• Filed: 03/01/2001
• Issued: 07/31/2007
• Est. Priority Date: 03/01/2000
• Status: Expired due to Fees

• Current Assignee: The Scripps Research Institute
• Original Assignee: The Scripps Research Institute
• Inventors: Boger, Dale L.
• Primary Examiner(s): Wilson; James O.
• Assistant Examiner(s): COLEMAN, BRENDA LIBBY
• Application Number:
  US10/204,787
• Publication Number:
  US 20030220320A1
• Time in Patent Office: 2,343 Days
• Field of Search: 514/214.01, 514/247, 514/411, 514/423, 540/576, 544/224, 548/430, 548/533
• US Class Current: 514/214.01
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07D 207/34 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• CPC Class Codes: C07D 237/24 Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• CPC Class Codes: C07D 491/04 Ortho-condensed systems
• CPC Class Codes: C07D 491/14 Ortho-condensed systems

Abstract

Anlogs of ningalin B lacking inherent cytotoxic activity may be employed to reverse multi-drug resistant (MDR) phenotype and to resensitize transformed cells, including a human colon cancer cell line (HCT116/VM46), with respect to a variety of cytotoxic agents, e.g., vinblastine and doxorubicin. In many instances, resensitization is achieved at lower doses than the prototypical agent verapamil. Total synthesis of ningalin B and its analogs was achieved using a concise, efficient approach based on a heterocyclic azadiene Diels-Alder strategy (1,2,4,5-tetrazine→1,2-diazine→pyrrole) ideally suited for construction of the densely functionalized pyrrole core found in the natural product is detailed.

Claims

1. A compound represented by the following structure:

2. A compound according to claim 1 represented by the following structure:

3. A compound according to claim 1 represented by the following structure:

4. A compound represented by the following structure:

5. A compound according to claim 4 represented by the following structure:

6. A compound according to claim 4 represented by the following structure:

7. A compound according to claim 4 represented by the following structure:

8. A compound according to claim 4 represented by the following structure:

9. An analog of ningalin B represented by the following structure:

20. A solution comprising a physiological buffer suitable for injection or infusion admixed a P-gp mediated multidrug resistance reversal agent having a concentration sufficient to resensitize a cancer cell having a resistance to an anticancer drug, the multidrug resistance reversal agent being selected from any of the compounds described in claim 9.

10. A synthetic process comprising the following step:

cyclizing a precursor compound with an excess of Eaton'"'"'s acid at room temperature under reaction conditions for producing an analog of ningalin B, the precursor compound, the analog of ningalin B, and the cyclization reaction being represented as follows;

11. A process for P-gp mediated reversing multidrug resistance in a cancer cell comprising the step of

contacting said cancer cell with a concentration sufficient for reversing said P-gp mediated multidrug resistance of a compound selected from a group consisting of compounds represented by the following structures:

12. A process according to claim 11 wherein the compound is represented by the following structure:

13. A process according to claim 11 wherein the compound is represented by the following structure:

14. A process according to claim 11 wherein the compound is represented by the following structure:

15. A process according to claim 11 wherein the compound is represented by the following structure:

16. A process according to claim 11 wherein the compound is represented by the following structure:

17. A process according to claim 11 wherein the compound is represented by the following structure:

18. A process according to claim 11 wherein the compound is represented by the following structure:

19. A process according to claim 11 wherein the compound is represented by the following structure: